Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480535 | 0.85 | ALDH1A1 (0.39) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL3147575 | 0.85 | MMP1 (0.38) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL28616526 | 0.84 | EED (0.39) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL19625254 | 0.80 | TAAR1 (0.37) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL8233608 | 0.79 | TAAR1 (0.43) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL15859765 | 0.79 | IDO1 (0.58) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL4798654 | 0.79 | MMP1 (0.40) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL4798648 | 0.79 | MMP1 (0.40) | MMP1MMP2MMP9MMP12TAAR1 | |
| SCHEMBL2352765 | 0.79 | MMP1 (0.44) | MMP1MMP2MMP9MMP12KDM4E | |
| SCHEMBL7684567 | 0.77 | MMP1 (0.43) | MMP1MMP2MMP9MMP12GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| EP-3813832-B1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) | 2022-11-09 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2008153278-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153277-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| CN-1293069-C | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2007-01-03 | — | — | CN | disclosed |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | JESCHKE PETER | 2006-08-03 | — | — | US | disclosed |
| US-7034130-B2 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-04-25 | — | — | US | disclosed |
| CN-1556802-A | Process for preparing novel spinosyn derivatives | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | MMP1 1861/4885MMP2 2590/4885MMP9 3871/4885 |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | MMP1 1861/4885MMP2 2590/4885MMP9 3871/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | MMP1 1571/4885MMP2 1138/4885MMP9 556/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | MMP1 3035/4885MMP2 1555/4885MMP9 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.